InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.145 0.055 (4.58%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$35 Trading Halt 21 Mar 2018 9:20AM $0.140 $1.140 risen by 714.29%
$35 OncoSil Company Update Presentation 8 Mar 2018 9:18AM $0.135 $1.140 risen by 744.44%
$35 Appendix 3B 2 Mar 2018 3:53PM $0.140 $1.140 risen by 714.29%
$35 Positive Early Study Results Continue 28 Feb 2018 9:20AM $0.145 $1.140 risen by 686.21%
$35 Appendix 4D & Half Yearly Report and Accounts 21 Feb 2018 11:59AM $0.135 $1.140 risen by 744.44%
$35 Change in substantial holding 8 Feb 2018 5:23PM $0.140 $1.140 risen by 714.29%
$35 First Subject Recruited in the United States 8 Feb 2018 9:40AM $0.140 $1.140 risen by 714.29%
$35 Response to ASX Appendix 4C Query 8 Feb 2018 9:29AM $0.140 $1.140 risen by 714.29%
$35 Change of Director's Interest Notice - Appendix 3Y 30 Jan 2018 1:16PM $0.140 $1.140 risen by 714.29%
$35 Change of Director's Interest Notice - Appendix 3Y 30 Jan 2018 1:15PM $0.140 $1.140 risen by 714.29%
$35 Final share buy-back notice - Appendix 3F 30 Jan 2018 9:04AM $0.145 $1.140 risen by 686.21%
$35 Appendix 4C & Quarterly Update 29 Jan 2018 9:34AM $0.145 $1.140 risen by 686.21%
$35 Additional Receipt of $0.6m R&D Tax Incentive Refund 16 Jan 2018 4:40PM $0.145 $1.140 risen by 686.21%
$35 Appendix 3C - Employee Loan Share Buy Back 11 Jan 2018 9:24AM $0.145 $1.140 risen by 686.21%
$35 20th Patient implanted with OncoSil device 10 Jan 2018 9:35AM $0.140 $1.140 risen by 714.29%
$35 Progress Update on Global Pancreatic Cancer Clinical Study 21 Dec 2017 9:33AM $0.155 $1.140 risen by 635.48%
$35 Loan Share Vesting Conditions Met 23 Nov 2017 4:16PM $0.130 $1.140 risen by 776.92%
$35 Appendix 4C & Quarterly Update 31 Oct 2017 9:22AM $0.125 $1.140 risen by 812%
$35 Change in substantial holding 26 Oct 2017 5:33PM $0.130 $1.140 risen by 776.92%
$35 Results of Annual General Meeting 2017 25 Oct 2017 3:21PM $0.140 $1.140 risen by 714.29%
$35 Australia Biotech Invest 2017 Presentation 24 Oct 2017 9:13AM $0.155 $1.140 risen by 635.48%
$35 Positive Early Study Results Presented at EANM Congress 23 Oct 2017 9:06AM $0.165 $1.140 risen by 590.91%
$35 Progress Update on Global Pancreatic Cancer Clinical Study 16 Oct 2017 9:36AM $0.125 $1.140 risen by 812%
$35 R&D Refund 25 Sep 2017 9:22AM $0.100 $1.140 risen by 1,040%
$35 Progress update on Global Pancreatic Cancer Clinical Study 22 Sep 2017 9:33AM $0.100 $1.140 risen by 1,040%

626 - 650 of 794 results

Page 26 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.